vVARDIS raises €45.0M Series C round
15 July 2025· Zug, Switzerland· health, dental_care, biomimetic, biotech, deep_tech, b2b
The funds aim to refinance existing facilities and accelerate the global expansion of Curodont™, a drill-free treatment for early tooth decay.
Investors
LeadOrbiMed
About vVARDIS
Stage
Series C
Headquarters
Zug, Switzerland
Founded
2003
Team Size
51–200
Sectors
healthdental_carebiomimeticbiotechdeep_techb2b